Meridian Bioscience | GenomeWeb

Meridian Bioscience

The firm has launched a line of 60 rapid immunoassays aimed at emerging markets, and plans to emphasize its menu to drive uptake of its molecular platform.

The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.

The firm provided updated guidance for the year, which also fell below analysts' estimates, and cut its annual indicated dividend rate.

Executives from Genomic Health, Meridian Bioscience, and Qiagen provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.

By detecting as little as one parasite per microliter of whole blood, the test could be used to further future efforts aimed at malaria eradication.

The results affirmed the company's preliminary earnings issued last month.

The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

The technology, called LAMP, produces DNA at a single temperature and at higher amounts than can be achieved with PCR-based amplification.

Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests. 

Pages

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.